Drug Development Pipeline
Lonodelestat (formerly POL6014)
Lonodelestat is a compound designed to block the function of neutrophil elastase. Neutrophil elastase is a type of protein associated with inflammation in the lungs. Blocking the function of neutrophil elastase may minimize tissue destruction and decrease inflammation within the CF airway.
Phase 1 studies to test the safety of this compound are underway in Europe.
This program is sponsored by Santhera and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More